Senator Sanders Letter to FDA: U.S. needs an ethical pathway for biological products
On November 2, 2010, U.S. Senator Bernard Sanders (VT-I) sent a letter to Margaret Hamburg, the FDA Commissioner, urging the agency to review the ethical implications of the 12 years of marketing exclusivity created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).